Key result
A competitive RIA for Urodilatin was developed with a detection limit of 10.5 ng/L, recoveries of 90-104%, and intraassay CVs around 8%, allowing measurement in urine and plasma.
A highly specific and sensitive competitive RIA was successfully developed for the direct measurement of urodilatin in urine and plasma without cross-reactivity to related natriuretic peptides.
Enables urodilatin quantification in urine and plasma; leaves open its clinical utility pending prospective validation.
Urodilatin (95-126) (URO) appears to play a major physiologic role in fluid homeostasis and produces major changes when administered intravenously. Here we describe a monospecific, high-affinity antiserum against URO with no cross-reactivity (<0.01%) against the structural highly homologous atrial natriuretic peptide 99-126 (ANP-99-126), ANP analogs, and related peptides such as brain natriuretic peptide. A competitive RIA was developed, based on this antiserum. Urine samples with or without ethanol extraction and plasma samples without pretreatment were analyzed by the RIA, which had a detection limit of 10.5 ng/L, a linear measuring range between 10.5 and 1000 ng/L, and recoveries of 93-102% in urine and 90-104% in plasma. The intraassay CVs were 8.2% and 8.1% for urine samples with 269 and 669 ng/L URO; the interassay CV was 9.7% at 839 ng/L. Using this assay, we present URO data for urine from healthy volunteers receiving low and routine sodium diets and from clinical urine specimens; we also present pharmacokinetic data for URO in plasma from patients suffering from bronchial asthma and treated by URO infusion.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (1998) studied Healthy volunteers and bronchial asthma. Urodilatin RIA assay was evaluated on Assay characteristics (detection limit, linear range, recoveries, CVs). A competitive RIA for Urodilatin was developed with a detection limit of 10.5 ng/L, recoveries of 90-104%, and intraassay CVs around 8%, allowing measurement in urine and plasma.